LakeShore Biopharma Co Ltd
LSB0.627USD
0.000
Market hours （ET）Quotes delayed by 15 min
13.02MMarket Cap
--P/E TTM
More Details of LakeShore Biopharma Co Ltd Company
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
LakeShore Biopharma Co Ltd Info
Ticker SymbolLSB
Company nameLakeShore Biopharma Co Ltd
IPO dateJul 30, 2021
CEOMr. Dave Chenn
Number of employees573
Security typeOrdinary Share
Fiscal year-endJul 30
AddressBuilding No. 2, 38 Yongda Road
CityBEIJING
Stock exchangeNASDAQ Capital Market Consolidated
CountryChina
Postal code102629
Phone
Websitehttps://www.ysbiopharm.com/
Ticker SymbolLSB
IPO dateJul 30, 2021
CEOMr. Dave Chenn
Company Executives of LakeShore Biopharma Co Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 2
Updated: Thu, Oct 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
Other
12.17%
Shareholders
Shareholders
Proportion
Crystal Peak Investment Inc
51.01%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
Shao (Hui)
0.76%
Fidelity Management & Research Company LLC
0.28%
Other
12.17%
Shareholder Types
Shareholders
Proportion
Corporation
74.87%
Individual Investor
12.67%
Investment Advisor
0.36%
Investment Advisor/Hedge Fund
0.26%
Private Equity
0.13%
Hedge Fund
0.04%
Other
11.67%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
323.47K
0.78%
-1.42M
2025Q2
28
16.97M
69.54%
+11.06M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Crystal Peak Investment Inc
21.02M
51.01%
+4.03M
+23.75%
Aug 26, 2025
Apex Prospect Ltd
9.84M
23.87%
+1.00
+0.00%
Jul 11, 2025
Zhang (Yi)
4.91M
11.91%
--
--
Jun 30, 2025
Shao (Hui)
313.64K
0.76%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
116.51K
0.28%
--
--
Jun 30, 2025
HHLR Advisors, Ltd.
75.18K
0.18%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
54.80K
0.13%
-85.63K
-60.98%
Jun 30, 2025
Superstring Capital Management LP
30.79K
0.07%
--
--
Jun 30, 2025
Barclays Bank PLC
24.76K
0.06%
--
--
Jun 30, 2025
Citadel Advisors LLC
14.96K
0.04%
+4.38K
+41.35%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Date
Type
Ratio
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
Sep 27, 2024
Merger
10→1
